DRUG
name pending profile ingest
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 43 | +6 | 2.67M | $187.62M | +9 | −3 |
| Q1 2026 | 40 | 0 | 3.54M | $258.23M | +3 | −3 |
| Q4 2025 | 41 | +2 | 2.93M | $229.38M | +5 | −3 |
| Q3 2025 | 13 | +3 | 1.21M | $73.26M | +3 | — |
| Q2 2025 | 8 | 0 | 770.31K | $20.11M | +2 | −2 |
| Q1 2025 | 5 | +2 | 553.22K | $19.95M | +2 | — |
| Q4 2024 | 3 | +3 | 308.07K | $11.10M | +3 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 200.00K | +50.9% | $7.21M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Millennium Management ✦ | 192.56K | +376.9% | $6.95M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 135.02K | -0.1% | $4.87M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Marshall Wace ✦ | 18.76K | New | $676,529 | 0.0% | New | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 18.76K | New | $676,529 | 0.0% | New | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 6.88K | New | $248,342 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $676,529 | 0.0% |
| Marshall Wace | $676,529 | 0.0% |
| Citadel Advisors | $248,342 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 92 holders, 9.18M shares, $669.40M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.